ALK-101

N/A

Report date: 2026/04/10 20:01:49

Base Information

Drug NameALK-101
Drug Alias NameALK-101ALK101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Epidermal growth factor receptor erbB1Anti-Hepatocyte growth factor receptor
TargetsEpidermal growth factor receptor erbB1Hepatocyte growth factor receptor
Therapy Area/IndicationsSolid tumoursLarge intestine neoplasmCarcinoma, Non-Small-Cell Lung +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Allink Biotherapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Allink Biotherapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursLarge intestine neoplasmCarcinoma, Non-Small-Cell Lung +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A